The Desmoid Tumor Research Foundation

May 2014

Desmoid-Type Fibromatosis and Pregnancy: A Multi-institutional Analysis of Recurrence and Obstetric Risk.

Author Information

Alessandro Gronchi,Amanda J Cannell,Axel Le Cesne,Carol J Swallow,Chandrajit P Raut,Chiara Colombo,Marco Fiore,Monica M Bertagnolli,Paolo G Casali,Rebecca A Gladdy,Sara Coppola,Suzanne George,Sylvie Bonvalot

*Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy †Department of Surgery, Institut Gustave Roussy, Villejuif, France ‡Division of General Surgery, Mount Sinai Hospital; Department of Surgical Oncology, Princess Margaret Hospital; and Department of Surgery, University of Toronto, Toronto, Ontario, Canada §Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ¶Department of Medical Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ‖Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France **Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Publication

Summary

Many women who present with desmoid-type fibromatosis (DF) have had a recent pregnancy. A cohort of women with DF and pregnancy was identified from 4 sarcoma centers. Progression/regression rates, recurrence rates after resection, and obstetric outcomes were analyzed. Pregnancy-related DF has good outcomes. Progression risk during pregnancy is high, but it can be safely managed. DF does not increase obstetric risk, and it should not be a contraindication to future pregnancy.

View Abstract